

Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/L137448CAEDEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: L137448CAEDEN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Understanding

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview

Lysine-specific demethylase 1 (LSD1) was the first histone demethylase discovered and conserved from fission yeast (*S. pombe*) to mammals. LSD1 played a pivotal role in a variety of biological processes like cell proliferation, adipogenesis, spermatogenesis, chromosome segregation, pluripotency regulation of stem cell and embryonic development. The discovery of LSD1 in 2004 demonstrated for the first time that histone methylation is a reversible reaction. LSD1 has three structural domains that regulate its enzymatic activity and binding to several proteins. Upon specific stimulation, LSD1 can also act as a transcriptional co-activator. LSD1 is structurally similar to the Flavin-

dependent monoamine oxidases (MAOs). Both LSD1 and MAOs utilize flavin adenine dinucleotide (FAD) as cofactor, thus, a number of known MAO inhibitors have been shown to also inhibit LSD1 through irreversible interaction of FAD. The overexpression of LSD1 is reported to be associated with different malignancies. Therefore, the inhibition of LSD1 provides a promising pharmacological target to investigate novel treatments for cancer and other disorders that associate with LSD1's activity.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lysine Specific Demethylase 1 (LSD-1) Inhibitor R&D. The therapies under development are focused on novel approaches for Lysine Specific Demethylase 1 (LSD-1) Inhibitor.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs Chapters

This segment of the Lysine Specific Demethylase 1 (LSD-1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs

ORY-2001: Oryzon Genomics

ORY-1001 is an oral, brain-permeable small molecule. It is a dual inhibitor of the transcriptional co-regulator lysine-specific demethylase 1 (LSD1 or KDM1A) and the mitochondrial membrane protein monoamine oxidase B. The drug is in Phase II clinical studies for the treatment of Aggression, Alzheimer's disease, Borderline personality disorders, Multiple sclerosis, and SARS-CoV-2 acute respiratory disease.

Domatinostat: 4SC

Domatinostat is an orally administered small molecule for the treatment of cancer. The

compound inhibits the enzymes histone deacetylase (HDAC) 1, 2, and 3, which are believed to play important roles in the regulation of aberrant cancer signaling. The drug is in Phase II clinical studies for the treatment of Gastrointestinal cancer; Merkel cell carcinoma and in Phase I/II clinical development for Malignant melanoma treatment.

Further product details are provided in the report.....

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Lysine Specific Demethylase 1 (LSD-1) Inhibitor

There are approx. 11+ key companies which are developing the Lysine Specific Demethylase 1 (LSD-1) Inhibitor. The companies which have their Lysine Specific Demethylase 1 (LSD-1) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Oryzon Genomics.

Phases

DelveInsight's report covers around 11+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Insights

- Lysine Specific Demethylase 1 (LSD-1) Inhibitor Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs?

How many Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Lysine Specific Demethylase 1 (LSD-1) Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Lysine Specific Demethylase 1 (LSD-1) Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Oryzon Genomics

4SC

Salarius Pharmaceuticals

Celgene Corporation

Taiho Pharmaceutical

CSPC ZhongQi Pharmaceutical Technology

Beatica

Rasna Therapeutics

Key Products

ORY-2001

Domatinostat

ORY-3001

Seclidemstat

CC-90011

TAS-1440

SYHA-1807

Research programme: small molecule therapeutics

RASP-201

Contents

Introduction

Executive Summary

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview

- Structure
- Mechanism of Action

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration

Lysine Specific Demethylase 1 (LSD-1) Inhibitor – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Lysine Specific Demethylase 1 (LSD-1) Inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

ORY-2001: Oryzon Genomics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

- Comparative Analysis

Seclidemstat: Salarius Pharmaceuticals

- Product Description

- Research and Development
- Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Research programme - small molecule therapeutics: Beatica
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report.....
- Inactive Products
- Comparative Analysis
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Products
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Unmet Needs
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Market Drivers and Barriers
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor- Future Perspectives and Conclusion
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor Analyst Views
- Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
- Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Lysine specific demethylase 1 inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Lysine specific demethylase 1 inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/L137448CAEDEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L137448CAEDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970